Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden Anstalt des öffentlichen Rechts des Freistaates Sachsen
ZKN Logo
  • The Center
    • Multiple Sclerosis Center Dresden
      • Patient Information
      • Contact MSC
      • Physicians & Nurses
      • Study Team
      • Neuropsychology
    • Mobility Center
      • The Mobility Center
      • Walking Assessment
      • Jump Assessment
      • DIERS
      • EMIQ
      • Projects
    • Neuroimmunological Laboratory
      • The NIL
      • Neurofilament light chain
    • Autonomic & Neuroendocrinological Functional Laboratory
      • The ANF
      • ANF Assessment
    • MS Living Lab
    • Management & Science
      • Team Management & Science
      • Projects
      • eHealth & Analytics
        • MSDS 3D
        • MSDS Clinic & Practice
        • MS-HRS
        • MTRS
      • Multiple Sclerosis Management
  • Aktuelles
    • Neuigkeiten
    • Publikationen
    • Veranstaltungen
      • Adventssymposium
      • Multiple Sklerose 360°
      • Welt-MS-Tag 2021
    • Doktorarbeiten
    • Jobs
    • Kontakt
  • Podcasts & Newsletter
    • Newsletter
    • Patienten-Podcast
    • Ärzte-Podcast
    • Neurovision
  • Studien
    • Interventionelle Studien
    • B-SHUTTLE
    • Nicht-interventionelle Studien
    • MS PATHS
    • Konectom
    • Sprachanalyse
English (UK)
Deutsch
English (UK)

Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA

MS Treatments

Jahr

Publikationsjahr
2024

Autoren

Autorenliste der Publikation
Yalachkov Y, Akgün K, Ziemssen T.

Verlag

Publisher-Information
Neuroimmunology Reports. 2024, 5:100211.

Link

Zur Publikation (externer Server)
https://doi.org/10.1016/j.nerep.2024.100211

Tags

Forschungsthemen
Multiple SkleroseMS Behandlung
MSZTreatments2024

  • RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

    Other
    Jahr
    2024

  • Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease

    Multiple Sclerosis
    Jahr
    2024

  • Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

    Multiple Sclerosis
    Jahr
    2024

  • MS brain health quality standards: a survey on the reality in clinical practice in Germany

    Multiple Sclerosis
    Jahr
    2024

  • Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

    MS Treatments
    Jahr
    2024
  • Start
  • Aktuelles
  • Publikationen
  • MS Treatments
  • Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA
Impressum & Datenschutz

© 2024
Universitätsklinikum C.G. Carus Dresden an der Technischen Universität Dresden